Amniotic membrane extract eye drops: a new approach to severe ocular surface pathologies

Pérez, Maria Luisa; Barreales, Saúl; Sabater-Cruz, Noelia; Martínez-Conesa, Eva M; Vilarrodona, Anna; Casaroli-Marano, Ricardo P.

doi:10.1007/s10561-021-09962-4

Cited by 17 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An experimental study showed that the area and intensity of corneal wound haze were significantly reduced in wounded ex vivo rabbit corneas treated with equine AME 32 . In human patients with acute chemical burns and corneal wound healing delay, the topical use of AME was helpful in suppressing inflammation, relieving symptoms, promoting epithelial healing, and restoring corneal stroma 33–35 …”

Section: Discussionmentioning

confidence: 99%

“…32 In human patients with acute chemical burns and corneal wound healing delay, the topical use of AME was helpful in suppressing inflammation, relieving symptoms, promoting epithelial healing, and restoring corneal stroma. [33][34][35] To date, in most of the studies that investigated the effects of the AMEs, the eye drops were manufactured at the institutions responsible for developing the research. 9,10,[12][13][14][15][16][17][18][19][20]32 In a clinical setting, the preparation and preservation of AME may be difficult or impracticable.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of commercial amniotic membrane extract on the re‐epithelialization time and the early expression of matrix metalloproteinase‐9 in cats with experimentally induced corneal ulcers

Silveira

Ribeiro

Pizzinatto

et al. 2022

Veterinary Ophthalmology

View full text Add to dashboard Cite

Objectives: To investigate whether a commercially available amniotic membrane extract (AME) can accelerate corneal wound healing and suppress the early expression of MMP-9 in the tears of cats with experimentally induced superficial ulcerative keratitis.Procedures: A total number of 16 cats were included. At the end of keratectomy, cats in the treatment group (TG, n = 8) received 40 μl of AME (EyeQ® Amniotic Eye Drops, Vetrix®) four times daily, while cats in the control group (CG, n = 8) received 40 μl of saline at the same time points. Tears were collected 24 and 48 h after keratectomy, and the total MMP-9 was quantified by ELISA. Results:The corneal re-epithelialization rate did not differ between groups (p = .26), being 0.48 ± 0.05 mm 2 /h in the CG and 0.41 ± 0.03 mm 2 /h in the TG.Similarly, the average time to achieve corneal wound healing did not differ between groups (p = .25) and was 61.50 ± 3.54 h in the CG and 70.50 ± 6.71 h in the TG. The dimensions of the ulcerated areas also did not differ at any time point between the groups (p > .05). In both groups, corneas healed without scarring, pigmentation, or vascularization. The expression of MMP-9 in the tears was similar in both groups at 24 h post-keratectomy, with a slight decrease at 48 h (p > .05). Conclusions:The instillation of a commercial AME (EyeQ®) is safe, but it did not decrease the corneal re-epithelialization time or the early expression of MMP-9 in the tears of cats with experimentally induced superficial ulcerative keratitis in this study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effects of commercial amniotic membrane extract on the re‐epithelialization time and the early expression of matrix metalloproteinase‐9 in cats with experimentally induced corneal ulcers

Silveira

Ribeiro

Pizzinatto

et al. 2022

Veterinary Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The results of phase I and II clinical trials were reported by Rita Piteira (Barcelona, Spain). In both trials, treatment with AMEED led to improvement in ocular surface symptoms, such as ocular pain, hyperaemia, eye stinging and burning [52,53]. A phase III trial is now underway.…”

Section: New Developmentsmentioning

confidence: 99%

Eye drops of human origin—Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies

et al. 2023

View full text Add to dashboard Cite

Background and Objectives Serum eye drops (SEDs) are used to treat ocular surface disease (OSD) and to promote ocular surface renewal. However, their use and production are not standardized, and several new forms of human eye drops have been developed. Materials and Methods The International Society for Blood Transfusion Working Party (ISBT WP) for Cellular Therapies held a workshop to review the current types of eye drops of human origin (EDHO) status and provide guidance. Results The ISBT WP for Cellular Therapies introduced the new terminology ‘EDHO’ to emphasize that these products are analogous to ‘medical products of human origin’. This concept encompasses their source (serum, platelet lysate, and cord blood) and the increasingly diverse spectrum of clinical usage in ophthalmology and the need for traceability. The workshop identified the wide variability in EDHO manufacturing, lack of harmonized quality and production standards, distribution issues, reimbursement schemes and regulations. EDHO use and efficacy is established for the treatment of OSD, especially for those refractory to conventional treatments. Conclusion Production and distribution of single‐donor donations are cumbersome and complex. The workshop participants agreed that allogeneic EDHO have advantages over autologous EDHO although more data on clinical efficacy and safety are needed. Allogeneic EDHOs enable more efficient production and, when pooled, can provide enhanced standardization for clinical consistency, provided optimal margin of virus safety is ensured. Newer products, including platelet‐lysate‐ and cord‐blood‐derived EDHO, show promise and benefits over SED, but their safety and efficacy are yet to be fully established. This workshop highlighted the need for harmonization of EDHO standards and guidelines.

show abstract

“…Amniotic membrane, the innermost layer of the placenta, is composed of a superiorly layer of epithelium, a basement membrane, and a rich stroma that promotes re-epithelialization, reduces inflammation and neovascularization through cytokines, growth factors, and other plasma proteins. [ 54 ] The amniotic membrane is available commercially in two main forms, cryopreserved and dehydrated. Treatment of moderate-to-severe DED with positive results has been reported with both forms of the amniotic membrane.…”

Section: Anti-inflammatory Therapiesmentioning

confidence: 99%

Dry eye disease

Nguyen¹,

Kolluru²,

Beglarian³

2023

Taiwan Journal of Ophthalmology

View full text Add to dashboard Cite

Dry eye disease (DED) is a common chronic ocular disease. DED can have a significant impact on visual function, causing disturbances to comfort, daily activities, and general quality of life. The varied nature of DED makes it difficult to point to a specific cause of the syndrome. However, current literature agrees that the inflammation of the cornea and conjunctiva plays a major role in its pathogenesis. Therapies targeted toward inflammation have shown varied success in the treatment of DED. The purpose of this review is to provide an overview of the prevalence and inflammatory pathophysiology of DED and discussion of the available anti-inflammatory therapies including the following: Nonsteroidal anti-inflammatory drugs, corticosteroids, and other hormonal therapies, nonsteroidal immunomodulators, biological tear replacement, antibiotics, dietary supplements, tea tree oil, and intense pulsed light.

show abstract

Amniotic membrane extract eye drops: a new approach to severe ocular surface pathologies

Cited by 17 publications

References 29 publications

Effects of commercial amniotic membrane extract on the re‐epithelialization time and the early expression of matrix metalloproteinase‐9 in cats with experimentally induced corneal ulcers

Effects of commercial amniotic membrane extract on the re‐epithelialization time and the early expression of matrix metalloproteinase‐9 in cats with experimentally induced corneal ulcers

Eye drops of human origin—Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies

Dry eye disease

Contact Info

Product

Resources

About